内镜下全层折叠术治疗PPI依赖性GERD:随机假手术对照试验
该随机假手术对照试验纳入70例PPI依赖性GERD患者,评估新型内镜下全层胃底折叠(EFTP)装置的有效性与安全性。主要终点为3个月时GERD-HRQL评分改善≥50%,EFTP组达标率65.7%显著高于假手术组2.9%。EFTP可安全改善生活质量,但客观指标应答有限。
要点
- EFTP术后3个月GERD-HRQL改善≥50%达标率65.7%,显著优于假手术组2.9%。
- 12个月时EFTP组62.8%停用PPI,假手术组仅11.4%。
- pH监测参数仅在3个月部分改善,12个月未见改善。
核心结论
- EFTP使用新型装置安全有效,可短期和长期改善以非糜烂性反流病为主的PPI依赖性GERD患者的生活质量。
- 客观参数应答率有限。
研究设计与样本
- 随机假手术对照试验,PPI依赖性GERD患者按1:1随机至EFTP组或假手术组。
- 共70例,每组35例,中位(IQR)年龄36(29-42)岁,男性占71.4%。
主要发现
- 主要终点(3个月GERD-HRQL改善≥50%)EFTP组65.7% vs 假手术组2.9%(p<0.001)。
- GERD-HRQL中位改善百分比在6个月为81.4(60.9-100.0)vs 8.0(2.2-21.6)(p<0.001),12个月为92.3(84.4-100.0)vs 9.1(4.8-36.0)(p<0.001)。
- 12个月停用PPI比例EFTP组62.8% vs 假手术组11.4%(p<0.001)。
- pH监测参数仅在3个月部分改善(n=70;EFTP组总反流次数及非酸反流次数),12个月未改善(n=27)。
- 12个月内镜下食管炎EFTP组0%(n=18),对照组5例(29.4%,n=17)。
关键数值与推荐
- 主要终点为3个月时GERD-HRQL评分改善≥50%。
- EFTP操作平均(±SD)时长17.4(±4)分钟。
- 70%患者内镜下为非糜烂性反流病,平均DeMeester评分18.9(±19.93)。
临床怎么用
- 对于PPI依赖性、以非糜烂性反流病为主的GERD患者,EFTP可作为改善生活质量和减少PPI使用的安全选择。
- 需告知患者客观反流参数改善可能有限。
局限性
- 12个月pH监测样本量仅27例,客观指标长期数据有限。
- 研究人群以非糜烂性反流病为主,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The majority of endoscopic antireflux procedures for GERD are cumbersome to use and randomised long-term data are sparse. We conducted such a trial to determine the efficacy and safety of a novel, easy to use endoscopic full-thickness fundoplication (EFTP) device in patients with GERD. DESIGN: Patients with proton pump inhibitor (PPI)-dependent GERD were randomised to either EFTP or a sham procedure in 1:1 ratio. The primary endpoint was ≥50% improvement in the health-related quality of life (GERD-HRQL) score at 3 months. Secondary end points included improvement in GERD-HRQL, reflux symptom scores, PPI usage, oesophageal acid exposure and reflux episodes and endoscopic findings at 3, 6 and 12 months. RESULTS: Seventy patients were randomised; 35 in each group with a median (IQR) age of 36 (29-42) years, 71.4% males. 70% had non-erosive reflux disease on endoscopy with a mean DeMeester score of 18.9 (±19.93). The mean (±SD) duration of EFTP procedure was 17.4 (±4) min. The primary end point was more frequently achieved in the EFTP group (65.7% vs 2.9%; p<0.001). Median (IQR) % improvement in GERD-HRQL was significantly higher in the EFTP group at 6 (81.4 (60.9-100.0) versus 8.0 (2.2-21.6); p<0.001) and 12 (92.3 (84.4-100.0) versus 9.1 (4.8-36.0); p<0.001) months. In the EFTP group, 62.8% patients were off-PPI at 12 months compared with 11.4% in the sham group (p<0.001). pH-metry parameters partially improved at 3 months, (n=70; total reflux episodes in EFTP arm and non-acid reflux episodes for EFTP vs sham) but not at 12 months (n=27); endoscopic oesophagitis was seen in 0% in the treatment (n=18) and 5 (29.4%) in the control group (n=17) at 12 months. No major procedure-related adverse events were encountered in either group. CONCLUSION: EFTP using a novel device is safe and effective in improving quality of life in patients with PPI dependent mostly non-erosive reflux disease at short and long terms; objective parameters showed a limited response rate. TRIAL REGISTRATION NUMBER: NCT03322553.
引用
- Kalapala R, Karyampudi A, Nabi Z, et al. Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: results from a randomised, sham controlled trial. Gut. 2021. PMID: 33849942. doi:10.1136/gutjnl-2020-321811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。